



PEACE, PROSPERITY AND  
REGIONAL INTEGRATION

## Update of Infection Prevention and Control measures during COVID-19 Pandemic





# Presentation Outline



- IPC strategies in Mass Gathering
- Conference Participants Testing Plan
- COVID-19 Update
- Vaccine response plan



# Current Global Situation 12<sup>th</sup> March, 2021




# COVID-19 Regional Case Load



- COVID-19 Updates: AFRO region: about 4.04m cases and 107,778 deaths
- Third wave seen in most member states
- Existence of a new variant
- Member states have eased restrictions and contact tracing and this are the number s \_\_\_\_\_

# Chain of Infection



# Standard Precautions Measures

Hand hygiene

Personal protective equipment ( Use of Mask)

Social Distancing (SD) – 1 Meter rule


Respiratory hygiene and cough etiquette

Cleaning and disinfection of devices and environmental surfaces

Safe injection practices

Medication storage and handling

## Infectious Droplets & Droplet Nuclei travel lengths



# Hand Hygiene: Emphasis



The term “hand hygiene” refers to the action of cleaning hands either by using:

**1. Soap and running water** commonly called **Hand Washing,**

Or

**2. Alcohol-base hand rub (ABHR)** referred to as **Hand Sanitizing**

**NB. ABHR used only when hands are not visibly soiled**

# In-country(KE) preventive and control Strategies

50 % capacity for mass gathering/ conference halls

Compulsory Use of Mask

Use of Sanitizers

Social Distancing (SD) at least 1.5 Metres

Temperature screening at business outlets, hotels, restaurants, mosques, churches, schools etc

Mandatory Screening at POE

Test Platform – (Polymerase Chain Reaction) PCR test

Test Validity Timeliness – 96 hours

restrictions within the country

- Dawn to dusk curfew ( 22:00 to 04:00hours)




www.shutterstock.com · 1685742598

Remember the 4 Key IPC Measures



# Correct use of Mask



shutterstock® IMAGE ID: 1760027390  
www.shutterstock.com



# IGAD conference participants testing plan-MOH KE

MOH supporting on site testing for IGAD meetings/ conferences in Kenya going forward

- **Supporting workshops/conferences held in Kenya**
- **Heads up at least 1 week before the event**
- **Must provide soft copy of participants details upfront**
- ***NO TESTING SUPPORT FOR INDIVIDUAL TESTING***

MOH COVID-19 testing Support;

- **Over 350 IGAD personal supported from October through February 2021**

Testing plan for this event:

- **MOH staffs prepared to conduct testing for all the participants**
- **A team of 2 RRT personnel will be available to support**
- **IGAD to provide logistics for the team**
- **sample collection room organized**
- **Provide accurate contacts to facilitate seamless submission of your results**
- **Soft copy results will be shared/sent to your email**
- **IGAD support measures put in place In case of positive covid test.**

# Everyday Preventive Actions- high index of *risk perception*

<b>Avoid</b>	Avoid touching your eyes, nose and mouth. Avoid close contact with people who are sick: Remember that some people without symptoms can still spread the virus(NSP) false positive reported
<b>Stay</b>	Stay at home when you are sick and seek medical attention
<b>Cover</b>	Cover your cough or sneeze with a tissue, then dispose it properly
<b>Use</b>	Use a face covering when physical distancing is difficult or when going into closed spaces Physical distancing should be at least 1 meter (3 ft)
<b>Clean and disinfect</b>	Clean and disinfect frequently touched objects and surfaces (sanitize)
<b>Perform</b>	Perform hand hygiene with soap and water or use alcohol-based hand rub. Hand Rub should contain at least 60% alcohol. Hand washing should be done for at least 40-60 seconds based on WHO's recommendations




# AstraZeneca Vaccine Suspension Region

No IGAD member state has suspended the vaccines

- Nigeria – stopped using one batch
- Cameroon and DRC have suspended

Reasons for suspension – not based on scientific evidence

- **no linkage between the Covid-19 vaccine** and deep vein thrombosis, pulmonary embolism and blood clotting
- Requires a lot of vaccine safety monitoring
- More research required to be studied



# IGAD MS (AstraZeneca/Serum Institute of India (SII) vaccine )

Member state	COVAX Facility Allocation	Vaccine Received	Vaccination began (Yes or No)	Target group
Sudan	2,904,000	820,000 doses	Yes	HCW
Djibouti	108,000	864,000**	No	HCW, people over 50 years of age and people with comorbidities
Kenya	3,564,000	1,020,000 doses	Yes, Mar 5	HCW ,
Uganda	3,024,000	864,000	Yes, Mar 10	
South Sudan	732,000			
Ethiopia	7,620,000	2,200,00	Yes, Mar 13	
Somalia	1,044,000	300,000	Yes, March 15	

# IGAD COVID vaccine response plan

**obj: Reduce morbidity and mortality due to COVID-19 and protect the Target Population**

**SO1: Increase Access to COVID -19 Vaccine in the Region**

Strengthened Coordination and Collaboration of Vaccine Deployment at the Regional level

Efficient procurement of COVID-19 Vaccines and other essential supplies

**SO2: Decrease Barriers to Efficient COVID-19 Vaccine Delivery and uptake**

Increased COVID-19 vaccine acceptance and uptake

Timely/rapid regulatory approval of COVID-19 vaccine in member states



# Vaccine Deployment Plan

IGAD Regional  
Vaccine Response  
Plan

Final Draft available

Target Population;  
IGAD staffs, cross  
border population,  
Refugees, IDP,s  
teachers

Approx. targeting  
5% of the Cross-  
border population  
in the IGAD region

**Resource mobilization: Budget  
estimated to be about USD 84 Million**

- Vaccine deployment including cold chain
- Interventions to mitigate impacts of COVID-19 in the region
- Strengthen Surveillance especially safety of vaccine
- Support continuum of care



Thank You  
Questions ?

